课题基金 / 基金详情

IMMUNOGLOBULIN ACCESS TO NEOANTIGENS ON CNS CELLS

IMMUNOGLOBULIN ACCESS TO NEOANTIGENS ON CNS CELLS
免疫球蛋白接触中枢神经系统细胞上的新抗原
批准号:
3400678
负责人:
Jerry Saul Wolinsky
金额:
$12.7万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-12-01 至 1986-11-30

项目摘要

项目成果

Jerry Saul Wolinsky的其他基金

相似基金

相关文献

中文摘要
翻译
在什么情况下抗原特异性免疫球蛋白被定义 同种异型能否进入中枢神经系统(CNS)以及这些 免疫球蛋白可以克服其扩散的潜在限制 沿着间质通路与表达的抗原相互作用 在神经细胞的表面上,基本上是未知的。尽管如此,CNS 免疫球蛋白的进入及其与神经细胞的相互作用 新抗原是目前几种致病理论的关键。 包括多发性硬化症在内的中枢神经系统自身免疫性疾病 多种中枢神经系统疾病的潜在免疫治疗。这项研究将 利用放射自显影和免疫组织化学两种方法 方法和批量转移研究,以确定是否、如何和何时转移 定义的单抗进入中枢神经系统是为了响应 新抗原出现在脑细胞表面。A最近 流行性腮腺炎糖蛋白单抗文库的研制 病毒、免疫细胞化学和放射自显影方法与井 描述的仓鼠流行性腮腺炎-脑膜脑炎模型结合形成 将用来处理这些问题的实验系统。
英文摘要
The circumstances under which antigen specific immunoglobulins of defined isotype can enter the central nervous system (CNS) and whether these immunoglobulins can overcome potential restrictions to their diffusion along interstitial pathways to reach and interact with antigens expressed on the surfaces of neural cells are essentially unknown. Despite this, CNS entry of immunoglobulins and their interaction with neural cells bearing neoantigens is critical to several current theories of the pathogenesis of autoimmune disorders of the CNS including multiple sclerosis and for the potential immunotherapy of a variety of CNS disorders. This study will utilize both autoradiographic and immunohistochemical morphologic approaches, and bulk transfer studies to determine whether, how and when defined monoclonal antibodies gain entry to the CNS in response to the appearance of neoantigens at the surfaces of brain cells. A recently developed library of monoclonal antibodies to the glycoproteins of mumps virus, immunocytochemical and autoradiographic approaches and the well described model of mumps-meningoencephalitis in hamsters combine to form the experimental system with which these problems will be approached.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY
海外基金